Abbott Laboratories vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Abbott Laboratories trades at $109.36 (market cap $187.95B), while Consumer Discretionary Select Sector SPDR Fund trades at $119.22. The key difference: Abbott Laboratories pays a 2.32% dividend while Consumer Discretionary Select Sector SPDR Fund pays none, and Consumer Discretionary Select Sector SPDR Fund is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | XLY | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | — |
52-Week High | $136.62 | $124.52 |
52-Week Low | $82.57 | $105.64 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
XLY trades at $119.86, up 1.47% with strong bullish technical momentum indicated by moving averages. Analyst consensus is unanimously positive with 100% buy ratings. The consumer discretionary ETF shows resilience amid economic uncertainty, with recent news highlighting its potential as a 'sleeper ETF' for Q3 2026. Technical indicators show overbought conditions on short-term RSI but strong trend momentum on ADX readings.
XLY presents a bullish case with strong technical momentum and unanimous analyst support, though current RSI levels suggest potential near-term consolidation. The ETF's performance hinges on consumer discretionary spending trends amid evolving inflation dynamics. Key risks include consumer confidence erosion and broader economic pressures affecting discretionary purchases.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →